Hangeshashinto for refractory overactive bladder

Effects of hangeshashinto for refractory overactive bladder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071200035

Enrollment

Registered

2020-10-05

Start date

2020-08-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory overactive bladder

Interventions

Hangeshashinto (7.5g daily, divide into 3 times) for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Aged 20 years or older 2.Patients with refractory overactive bladder 3.Has remaining symptoms(Frequency of the urinary urgency is once a week and OABSS total score >= 3) after anticholinergic or B stimulant drug treatment for 12 weeks or more 4.Written informed consent

Exclusion criteria

Exclusion criteria: 1.Urinary tract infection 2.Urological malignant cancer 3.Neurogenic bladder 4.Catheterization 5.Lower urinary tract obstruction 6.Heart, liver, and renal dysfunction, or blood abnormalities 7.Primary aldosteronism 8.Myopathy 9.Hypokalemia 10.Allergy to hangeshashinto 11.Elderly, dementia, or hard to answer questions 12.Decision by the attending physician

Design outcomes

Primary

Measure	Time frame
OABSS total score	—

Secondary

Measure	Time frame
IPSS voiding symptom QOL Residual urine volume,adverse events	—

Contacts

Public ContactMinoru Miyazato

University of the Ryukyus

miyaz929@med.u-ryukyu.ac.jp+81-98-895-1110

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026